| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 49 | 2024 | 177 | 12.530 |
Why?
|
| Venous Thrombosis | 54 | 2021 | 264 | 7.360 |
Why?
|
| Anticoagulants | 56 | 2024 | 484 | 5.590 |
Why?
|
| Risk Assessment | 47 | 2024 | 2599 | 3.590 |
Why?
|
| Pulmonary Embolism | 30 | 2024 | 234 | 3.150 |
Why?
|
| Thrombosis | 17 | 2024 | 318 | 2.980 |
Why?
|
| Thromboembolism | 28 | 2020 | 123 | 2.170 |
Why?
|
| Postoperative Complications | 46 | 2023 | 2687 | 2.140 |
Why?
|
| Fibrinolytic Agents | 17 | 2020 | 244 | 1.680 |
Why?
|
| Intermittent Pneumatic Compression Devices | 9 | 2021 | 11 | 1.680 |
Why?
|
| Arthroplasty, Replacement, Hip | 8 | 2023 | 108 | 1.510 |
Why?
|
| Orthopedic Procedures | 9 | 2020 | 159 | 1.410 |
Why?
|
| Risk Factors | 56 | 2024 | 6271 | 1.360 |
Why?
|
| Stockings, Compression | 5 | 2019 | 6 | 1.340 |
Why?
|
| Hemorrhage | 22 | 2022 | 296 | 1.290 |
Why?
|
| Heparin, Low-Molecular-Weight | 13 | 2021 | 33 | 1.290 |
Why?
|
| Orthopedics | 5 | 2020 | 142 | 1.190 |
Why?
|
| Humans | 197 | 2024 | 98363 | 1.040 |
Why?
|
| Neoplasms | 17 | 2023 | 3348 | 0.910 |
Why?
|
| Lower Extremity | 5 | 2023 | 112 | 0.830 |
Why?
|
| Benzimidazoles | 5 | 2012 | 118 | 0.820 |
Why?
|
| Venous Insufficiency | 7 | 2016 | 13 | 0.790 |
Why?
|
| Vascular Diseases | 3 | 2015 | 119 | 0.790 |
Why?
|
| Practice Guidelines as Topic | 14 | 2020 | 1116 | 0.770 |
Why?
|
| Pyridines | 5 | 2012 | 316 | 0.760 |
Why?
|
| Edema | 2 | 2015 | 68 | 0.750 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2023 | 67 | 0.720 |
Why?
|
| Arthroplasty | 2 | 2019 | 40 | 0.690 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2012 | 120 | 0.690 |
Why?
|
| Blood Coagulation | 22 | 2014 | 90 | 0.680 |
Why?
|
| Femoral Vein | 3 | 2021 | 42 | 0.680 |
Why?
|
| Thrombelastography | 23 | 1995 | 48 | 0.670 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 1785 | 0.660 |
Why?
|
| Blood Flow Velocity | 2 | 2021 | 179 | 0.640 |
Why?
|
| Perioperative Care | 4 | 2020 | 196 | 0.620 |
Why?
|
| Incidence | 15 | 2020 | 1787 | 0.600 |
Why?
|
| Warfarin | 10 | 2015 | 109 | 0.590 |
Why?
|
| Abdomen | 4 | 2008 | 121 | 0.580 |
Why?
|
| Guideline Adherence | 6 | 2016 | 250 | 0.580 |
Why?
|
| Bandages | 11 | 2014 | 43 | 0.560 |
Why?
|
| Veins | 5 | 2016 | 87 | 0.550 |
Why?
|
| Thrombophlebitis | 11 | 2020 | 24 | 0.550 |
Why?
|
| Middle Aged | 59 | 2021 | 29532 | 0.510 |
Why?
|
| Fractures, Bone | 1 | 2019 | 164 | 0.510 |
Why?
|
| Male | 68 | 2021 | 47257 | 0.510 |
Why?
|
| Language | 2 | 2020 | 165 | 0.500 |
Why?
|
| Female | 79 | 2023 | 51756 | 0.500 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 194 | 0.500 |
Why?
|
| Aged | 53 | 2021 | 21844 | 0.500 |
Why?
|
| Leg | 9 | 2022 | 145 | 0.490 |
Why?
|
| Compression Bandages | 2 | 2020 | 6 | 0.490 |
Why?
|
| Heparin | 21 | 2007 | 182 | 0.490 |
Why?
|
| Ultrasonography, Doppler, Duplex | 8 | 2021 | 42 | 0.480 |
Why?
|
| Enoxaparin | 5 | 2010 | 27 | 0.480 |
Why?
|
| Thrombophilia | 4 | 2020 | 22 | 0.470 |
Why?
|
| Registries | 10 | 2020 | 1127 | 0.430 |
Why?
|
| Foot Injuries | 1 | 2014 | 13 | 0.420 |
Why?
|
| Ankle Injuries | 1 | 2014 | 37 | 0.410 |
Why?
|
| Dabigatran | 7 | 2020 | 25 | 0.410 |
Why?
|
| Aspirin | 3 | 2012 | 168 | 0.410 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 2017 | 0.410 |
Why?
|
| Administration, Oral | 9 | 2019 | 676 | 0.370 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 7418 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2009 | 663 | 0.360 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 55 | 0.340 |
Why?
|
| Cholecystectomy, Laparoscopic | 5 | 1997 | 52 | 0.340 |
Why?
|
| Thrombin | 3 | 2008 | 60 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 602 | 0.340 |
Why?
|
| Preventive Health Services | 2 | 2010 | 38 | 0.340 |
Why?
|
| Sclerotherapy | 2 | 2023 | 20 | 0.340 |
Why?
|
| Contraindications | 5 | 2023 | 66 | 0.330 |
Why?
|
| Varicose Veins | 2 | 2022 | 12 | 0.320 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 8 | 2021 | 31 | 0.310 |
Why?
|
| Homocysteine | 2 | 2007 | 31 | 0.310 |
Why?
|
| Surgical Procedures, Operative | 5 | 2019 | 224 | 0.310 |
Why?
|
| Hyperhomocysteinemia | 2 | 2007 | 11 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 255 | 0.310 |
Why?
|
| Counterpulsation | 1 | 2009 | 21 | 0.300 |
Why?
|
| Retrospective Studies | 15 | 2023 | 11039 | 0.300 |
Why?
|
| Equipment Design | 2 | 2010 | 425 | 0.300 |
Why?
|
| General Surgery | 5 | 2015 | 264 | 0.300 |
Why?
|
| Blood Transfusion | 2 | 2020 | 179 | 0.290 |
Why?
|
| Drugs, Investigational | 1 | 2009 | 36 | 0.290 |
Why?
|
| Adult | 43 | 2023 | 29587 | 0.290 |
Why?
|
| Blood Coagulation Disorders | 9 | 1995 | 66 | 0.290 |
Why?
|
| Patient Discharge | 4 | 2011 | 381 | 0.290 |
Why?
|
| Travel | 3 | 2009 | 77 | 0.280 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 460 | 0.270 |
Why?
|
| Evidence-Based Medicine | 9 | 2020 | 481 | 0.270 |
Why?
|
| Prothrombin | 4 | 2005 | 19 | 0.270 |
Why?
|
| Laparotomy | 1 | 2008 | 65 | 0.270 |
Why?
|
| Elective Surgical Procedures | 3 | 2020 | 171 | 0.260 |
Why?
|
| Betacoronavirus | 2 | 2020 | 286 | 0.250 |
Why?
|
| Treatment Outcome | 22 | 2020 | 9770 | 0.240 |
Why?
|
| Factor Xa Inhibitors | 4 | 2020 | 24 | 0.240 |
Why?
|
| Gravity Suits | 3 | 2001 | 3 | 0.220 |
Why?
|
| Disease Management | 3 | 2023 | 377 | 0.220 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 341 | 0.220 |
Why?
|
| Drug Administration Schedule | 6 | 2020 | 837 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 337 | 0.210 |
Why?
|
| Prospective Studies | 15 | 2022 | 4818 | 0.210 |
Why?
|
| Attitude of Health Personnel | 4 | 2010 | 686 | 0.210 |
Why?
|
| Ultrasonography | 5 | 2018 | 720 | 0.210 |
Why?
|
| United States | 15 | 2018 | 8258 | 0.200 |
Why?
|
| Pandemics | 2 | 2020 | 913 | 0.200 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 3032 | 0.200 |
Why?
|
| Rivaroxaban | 2 | 2020 | 11 | 0.200 |
Why?
|
| Hospitalization | 3 | 2021 | 988 | 0.190 |
Why?
|
| Embolism | 1 | 2023 | 32 | 0.190 |
Why?
|
| Postthrombotic Syndrome | 2 | 2014 | 3 | 0.190 |
Why?
|
| Postoperative Care | 6 | 2019 | 237 | 0.190 |
Why?
|
| Time Factors | 15 | 2020 | 5576 | 0.190 |
Why?
|
| Pyridones | 2 | 2020 | 75 | 0.190 |
Why?
|
| Biomarkers | 5 | 2020 | 2021 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2020 | 160 | 0.180 |
Why?
|
| Psychometrics | 1 | 2003 | 356 | 0.180 |
Why?
|
| Cost of Illness | 1 | 2003 | 165 | 0.180 |
Why?
|
| Recurrence | 7 | 2017 | 1264 | 0.170 |
Why?
|
| Lymphatic Diseases | 2 | 2020 | 31 | 0.170 |
Why?
|
| Premedication | 2 | 2017 | 57 | 0.170 |
Why?
|
| Russia | 1 | 2021 | 29 | 0.170 |
Why?
|
| Aerospace Medicine | 1 | 2001 | 17 | 0.170 |
Why?
|
| Quality of Life | 4 | 2014 | 1899 | 0.170 |
Why?
|
| Fibrinolysis | 5 | 1995 | 35 | 0.160 |
Why?
|
| Perioperative Period | 2 | 2017 | 31 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2003 | 259 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2020 | 42 | 0.160 |
Why?
|
| Monitoring, Physiologic | 4 | 2006 | 265 | 0.160 |
Why?
|
| Saphenous Vein | 2 | 2019 | 61 | 0.160 |
Why?
|
| Injections, Subcutaneous | 5 | 2010 | 141 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 45 | 0.160 |
Why?
|
| Blood Loss, Surgical | 1 | 2020 | 140 | 0.150 |
Why?
|
| Communication | 1 | 2023 | 456 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2017 | 970 | 0.150 |
Why?
|
| Clinical Trials as Topic | 11 | 2020 | 1126 | 0.150 |
Why?
|
| Phlebography | 2 | 2018 | 74 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2001 | 231 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 170 | 0.140 |
Why?
|
| Mass Screening | 3 | 2010 | 751 | 0.140 |
Why?
|
| Pregnancy | 5 | 2023 | 3269 | 0.140 |
Why?
|
| Peptide Fragments | 2 | 2003 | 480 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 813 | 0.140 |
Why?
|
| Blood Platelets | 9 | 1988 | 153 | 0.130 |
Why?
|
| Translating | 1 | 2017 | 17 | 0.130 |
Why?
|
| Clothing | 3 | 1988 | 7 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2018 | 96 | 0.130 |
Why?
|
| Cholangiography | 4 | 1994 | 38 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2019 | 3227 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2018 | 93 | 0.130 |
Why?
|
| Long-Term Care | 2 | 2011 | 66 | 0.130 |
Why?
|
| Oxygen | 3 | 2001 | 773 | 0.120 |
Why?
|
| Precision Medicine | 2 | 2019 | 502 | 0.120 |
Why?
|
| Polysaccharides | 2 | 2007 | 100 | 0.120 |
Why?
|
| Cholelithiasis | 4 | 1994 | 36 | 0.120 |
Why?
|
| Follow-Up Studies | 10 | 2005 | 4044 | 0.120 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2007 | 28 | 0.120 |
Why?
|
| Acute Disease | 7 | 2008 | 860 | 0.120 |
Why?
|
| Prothrombin Time | 8 | 2018 | 18 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 684 | 0.110 |
Why?
|
| Upper Extremity | 1 | 2016 | 69 | 0.110 |
Why?
|
| Abdominal Muscles | 2 | 1995 | 26 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2017 | 510 | 0.110 |
Why?
|
| Dihydroergotamine | 1 | 1995 | 1 | 0.110 |
Why?
|
| Factor V | 2 | 2005 | 9 | 0.110 |
Why?
|
| Gallstones | 2 | 1988 | 21 | 0.110 |
Why?
|
| Risk | 2 | 2017 | 660 | 0.110 |
Why?
|
| Tourniquets | 1 | 1994 | 10 | 0.110 |
Why?
|
| Tissue Adhesions | 1 | 1995 | 55 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1947 | 0.110 |
Why?
|
| Platelet Activation | 1 | 2014 | 18 | 0.110 |
Why?
|
| Antithrombins | 1 | 2014 | 20 | 0.110 |
Why?
|
| Varicose Ulcer | 1 | 2014 | 6 | 0.100 |
Why?
|
| Vitamin K | 1 | 2014 | 27 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2017 | 1529 | 0.100 |
Why?
|
| Inpatients | 2 | 2016 | 367 | 0.100 |
Why?
|
| Elasticity | 3 | 2010 | 98 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2015 | 1790 | 0.100 |
Why?
|
| Health Services Research | 2 | 2005 | 145 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 5 | 2013 | 525 | 0.090 |
Why?
|
| Clinical Protocols | 3 | 2015 | 156 | 0.090 |
Why?
|
| Hemodynamics | 2 | 2016 | 746 | 0.090 |
Why?
|
| Partial Thromboplastin Time | 6 | 1999 | 17 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1995 | 162 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 765 | 0.090 |
Why?
|
| Acute Coronary Syndrome | 1 | 2012 | 31 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 239 | 0.090 |
Why?
|
| Hemostasis | 2 | 1995 | 25 | 0.090 |
Why?
|
| Biliary Tract | 1 | 1991 | 11 | 0.080 |
Why?
|
| Fibrinolysin | 3 | 1988 | 25 | 0.080 |
Why?
|
| Europe | 3 | 2008 | 357 | 0.080 |
Why?
|
| Awareness | 2 | 2009 | 93 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 71 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 7568 | 0.080 |
Why?
|
| Blood Coagulation Tests | 7 | 1985 | 31 | 0.080 |
Why?
|
| Prognosis | 8 | 2017 | 4126 | 0.080 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 20 | 0.080 |
Why?
|
| Algorithms | 1 | 2018 | 2003 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 402 | 0.080 |
Why?
|
| Blood Coagulation Factors | 4 | 2004 | 20 | 0.070 |
Why?
|
| Intraoperative Complications | 3 | 1995 | 195 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2005 | 2009 | 0.070 |
Why?
|
| Probability | 2 | 2008 | 356 | 0.070 |
Why?
|
| Plasminogen Activators | 2 | 1996 | 10 | 0.070 |
Why?
|
| Pulmonary Veins | 2 | 2020 | 118 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 992 | 0.070 |
Why?
|
| Posture | 3 | 2006 | 124 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 86 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 109 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2792 | 0.070 |
Why?
|
| Consensus | 2 | 2020 | 309 | 0.070 |
Why?
|
| Arthroplasty, Replacement | 1 | 2008 | 34 | 0.070 |
Why?
|
| North America | 1 | 2008 | 210 | 0.070 |
Why?
|
| Dogs | 10 | 1995 | 642 | 0.070 |
Why?
|
| Health Promotion | 1 | 2009 | 175 | 0.070 |
Why?
|
| Ferrosoferric Oxide | 1 | 2007 | 19 | 0.060 |
Why?
|
| Health Policy | 1 | 2009 | 217 | 0.060 |
Why?
|
| Streptokinase | 1 | 1986 | 10 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 302 | 0.060 |
Why?
|
| Pneumoperitoneum, Artificial | 2 | 1994 | 8 | 0.060 |
Why?
|
| Patient Outcome Assessment | 2 | 2017 | 90 | 0.060 |
Why?
|
| Animals | 17 | 2013 | 28981 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2011 | 1752 | 0.060 |
Why?
|
| Surgical Instruments | 2 | 1985 | 70 | 0.060 |
Why?
|
| Length of Stay | 2 | 2016 | 876 | 0.060 |
Why?
|
| Catheterization | 5 | 1994 | 220 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2008 | 687 | 0.060 |
Why?
|
| Reference Standards | 3 | 1995 | 147 | 0.060 |
Why?
|
| Internationality | 2 | 2019 | 80 | 0.060 |
Why?
|
| Survival Rate | 2 | 2012 | 2050 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2010 | 602 | 0.060 |
Why?
|
| Blood Circulation | 1 | 2005 | 29 | 0.060 |
Why?
|
| Canada | 2 | 2017 | 210 | 0.060 |
Why?
|
| Elastic Tissue | 1 | 2005 | 18 | 0.060 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2005 | 4 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1009 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 48 | 0.060 |
Why?
|
| Comorbidity | 1 | 2009 | 1035 | 0.060 |
Why?
|
| Monte Carlo Method | 2 | 2003 | 194 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 169 | 0.060 |
Why?
|
| Aftercare | 1 | 2006 | 92 | 0.060 |
Why?
|
| Catheters | 2 | 2016 | 109 | 0.050 |
Why?
|
| Blood Specimen Collection | 2 | 1995 | 29 | 0.050 |
Why?
|
| BCG Vaccine | 3 | 1984 | 44 | 0.050 |
Why?
|
| Arteries | 1 | 2005 | 172 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2005 | 471 | 0.050 |
Why?
|
| Monocytes | 1 | 2005 | 220 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 291 | 0.050 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2004 | 17 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2007 | 503 | 0.050 |
Why?
|
| Perfusion | 1 | 2005 | 271 | 0.050 |
Why?
|
| Professional Practice | 1 | 2003 | 43 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 405 | 0.050 |
Why?
|
| Plasminogen | 6 | 1988 | 45 | 0.050 |
Why?
|
| Models, Econometric | 1 | 2003 | 15 | 0.050 |
Why?
|
| Mutation | 2 | 2005 | 4428 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 1945 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2003 | 93 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2005 | 1094 | 0.050 |
Why?
|
| Cost Savings | 1 | 2003 | 68 | 0.050 |
Why?
|
| Breast Neoplasms | 7 | 2005 | 3285 | 0.050 |
Why?
|
| Markov Chains | 1 | 2003 | 147 | 0.050 |
Why?
|
| Models, Economic | 1 | 2002 | 63 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2003 | 387 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2003 | 168 | 0.040 |
Why?
|
| Plethysmography | 1 | 2001 | 16 | 0.040 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2001 | 10 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2011 | 726 | 0.040 |
Why?
|
| Foot | 1 | 2001 | 64 | 0.040 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 1994 | 73 | 0.040 |
Why?
|
| Computers | 2 | 1979 | 103 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 4 | 1995 | 29 | 0.040 |
Why?
|
| Peptide Hydrolases | 2 | 1988 | 99 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2002 | 282 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2005 | 606 | 0.040 |
Why?
|
| Hematocrit | 7 | 1988 | 68 | 0.040 |
Why?
|
| Adolescent | 6 | 2019 | 10137 | 0.040 |
Why?
|
| Drug Combinations | 2 | 1995 | 201 | 0.040 |
Why?
|
| Common Bile Duct | 1 | 1980 | 19 | 0.040 |
Why?
|
| Gallbladder Diseases | 1 | 1980 | 21 | 0.040 |
Why?
|
| Peritoneum | 1 | 1980 | 52 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2020 | 19 | 0.040 |
Why?
|
| Postoperative Period | 2 | 1999 | 321 | 0.040 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1999 | 9 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 1999 | 5 | 0.040 |
Why?
|
| Prostatic Neoplasms | 2 | 2003 | 1842 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2000 | 52 | 0.040 |
Why?
|
| Pressure | 2 | 1994 | 174 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 1996 | 25 | 0.040 |
Why?
|
| Immunoassay | 1 | 1999 | 102 | 0.040 |
Why?
|
| Dextrans | 1 | 1979 | 77 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2018 | 13 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 1979 | 36 | 0.040 |
Why?
|
| Burns | 2 | 1978 | 150 | 0.030 |
Why?
|
| Lipoproteins | 2 | 1996 | 136 | 0.030 |
Why?
|
| Diatomaceous Earth | 2 | 1995 | 3 | 0.030 |
Why?
|
| Operating Room Nursing | 1 | 1978 | 1 | 0.030 |
Why?
|
| Hernia, Ventral | 1 | 1978 | 31 | 0.030 |
Why?
|
| Data Display | 1 | 1978 | 19 | 0.030 |
Why?
|
| Electronics | 1 | 1978 | 21 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 1999 | 420 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 1979 | 140 | 0.030 |
Why?
|
| China | 1 | 2018 | 277 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 440 | 0.030 |
Why?
|
| Ovary | 1 | 1979 | 262 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 284 | 0.030 |
Why?
|
| Popliteal Vein | 3 | 1995 | 4 | 0.030 |
Why?
|
| Preoperative Care | 3 | 1995 | 418 | 0.030 |
Why?
|
| Fibrin | 2 | 1995 | 86 | 0.030 |
Why?
|
| Mastectomy | 2 | 1980 | 273 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 305 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2056 | 0.030 |
Why?
|
| Calcium | 3 | 1995 | 1203 | 0.030 |
Why?
|
| Hemostatics | 2 | 1974 | 64 | 0.030 |
Why?
|
| Platelet Count | 4 | 1995 | 94 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 1997 | 98 | 0.030 |
Why?
|
| Endothelins | 1 | 1995 | 26 | 0.030 |
Why?
|
| Thrombolytic Therapy | 3 | 2007 | 261 | 0.030 |
Why?
|
| Hypoxia | 1 | 2001 | 682 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2016 | 194 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1276 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 1995 | 14 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 450 | 0.030 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 18 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 300 | 0.030 |
Why?
|
| Documentation | 1 | 2016 | 112 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1995 | 59 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1995 | 68 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3612 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1997 | 321 | 0.030 |
Why?
|
| Rabbits | 2 | 1995 | 582 | 0.030 |
Why?
|
| Walking | 1 | 2016 | 114 | 0.030 |
Why?
|
| Transplantation | 1 | 1995 | 39 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1995 | 214 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2005 | 420 | 0.030 |
Why?
|
| Disposable Equipment | 1 | 1994 | 25 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 2548 | 0.030 |
Why?
|
| Pressure Ulcer | 1 | 2014 | 45 | 0.030 |
Why?
|
| Cause of Death | 2 | 2005 | 278 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1974 | 0.020 |
Why?
|
| Fibrinogen | 6 | 1987 | 48 | 0.020 |
Why?
|
| Artifacts | 1 | 1995 | 248 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 408 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 651 | 0.020 |
Why?
|
| Remission Induction | 1 | 1995 | 764 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1995 | 337 | 0.020 |
Why?
|
| Infant | 1 | 2019 | 3358 | 0.020 |
Why?
|
| In Vitro Techniques | 4 | 2005 | 945 | 0.020 |
Why?
|
| Wound Healing | 1 | 2014 | 384 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 4038 | 0.020 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 1991 | 13 | 0.020 |
Why?
|
| Biliary Fistula | 1 | 1991 | 12 | 0.020 |
Why?
|
| Rupture | 1 | 1991 | 59 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 1991 | 26 | 0.020 |
Why?
|
| Intestinal Fistula | 1 | 1991 | 32 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 1167 | 0.020 |
Why?
|
| Wounds, Penetrating | 1 | 1991 | 68 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 1983 | 47 | 0.020 |
Why?
|
| Radiography | 2 | 1991 | 763 | 0.020 |
Why?
|
| Platelet Aggregation | 2 | 1988 | 40 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 220 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 141 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 72 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.020 |
Why?
|
| Thromboplastin | 2 | 2007 | 8 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 20 | 0.020 |
Why?
|
| Intubation | 1 | 1988 | 21 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 171 | 0.020 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1988 | 6 | 0.020 |
Why?
|
| Antithrombin III | 1 | 1988 | 9 | 0.020 |
Why?
|
| Argentina | 1 | 2008 | 15 | 0.020 |
Why?
|
| Israel | 1 | 2008 | 69 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1995 | 795 | 0.020 |
Why?
|
| Vena Cava Filters | 2 | 2003 | 92 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 176 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 1988 | 139 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 211 | 0.020 |
Why?
|
| Hematoma | 3 | 1977 | 106 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 4074 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 1984 | 1539 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2010 | 318 | 0.020 |
Why?
|
| Child | 1 | 2019 | 7745 | 0.020 |
Why?
|
| Statistics as Topic | 4 | 1981 | 229 | 0.020 |
Why?
|
| P-Selectin | 1 | 2007 | 14 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 210 | 0.020 |
Why?
|
| Melphalan | 3 | 1984 | 98 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 218 | 0.020 |
Why?
|
| Caseins | 1 | 1986 | 9 | 0.020 |
Why?
|
| Plasma | 3 | 1995 | 49 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1986 | 49 | 0.020 |
Why?
|
| Factor XII | 2 | 1977 | 2 | 0.010 |
Why?
|
| Textiles | 1 | 2006 | 2 | 0.010 |
Why?
|
| Random Allocation | 2 | 1984 | 312 | 0.010 |
Why?
|
| Thrombectomy | 1 | 2008 | 265 | 0.010 |
Why?
|
| Decision Making | 1 | 1991 | 689 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 452 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2005 | 45 | 0.010 |
Why?
|
| Calibration | 1 | 2006 | 109 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2005 | 16 | 0.010 |
Why?
|
| Knee Joint | 2 | 1977 | 179 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2005 | 31 | 0.010 |
Why?
|
| Quality Control | 1 | 2006 | 131 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1985 | 92 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 419 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2005 | 96 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 988 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 281 | 0.010 |
Why?
|
| Aircraft | 1 | 2005 | 26 | 0.010 |
Why?
|
| Autopsy | 1 | 2005 | 131 | 0.010 |
Why?
|
| Immobilization | 1 | 2004 | 21 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 446 | 0.010 |
Why?
|
| Leukocytes | 1 | 2005 | 214 | 0.010 |
Why?
|
| Reference Values | 2 | 1995 | 608 | 0.010 |
Why?
|
| Nematode Infections | 1 | 1983 | 4 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2006 | 517 | 0.010 |
Why?
|
| Eosinophilic Granuloma | 1 | 1983 | 9 | 0.010 |
Why?
|
| Spain | 1 | 2003 | 36 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 565 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1984 | 177 | 0.010 |
Why?
|
| Omentum | 1 | 1983 | 69 | 0.010 |
Why?
|
| Ischemia | 1 | 2005 | 263 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 1145 | 0.010 |
Why?
|
| Appendicitis | 1 | 1983 | 70 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 1255 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1987 | 448 | 0.010 |
Why?
|
| Contrast Media | 1 | 2007 | 1013 | 0.010 |
Why?
|
| Amino Acids | 1 | 2003 | 247 | 0.010 |
Why?
|
| Drug Costs | 1 | 2002 | 66 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2002 | 186 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 283 | 0.010 |
Why?
|
| Complement C4 | 2 | 1980 | 8 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 402 | 0.010 |
Why?
|
| Complement C3 | 2 | 1980 | 62 | 0.010 |
Why?
|
| Cholecystitis | 1 | 1980 | 17 | 0.010 |
Why?
|
| Methods | 1 | 1980 | 134 | 0.010 |
Why?
|
| Injections | 2 | 1979 | 131 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1980 | 71 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1980 | 74 | 0.010 |
Why?
|
| Kallikreins | 2 | 1978 | 47 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1980 | 65 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1980 | 76 | 0.010 |
Why?
|
| Microscopy | 1 | 1980 | 92 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 1982 | 2381 | 0.010 |
Why?
|
| Leukemia | 1 | 1982 | 309 | 0.010 |
Why?
|
| Drainage | 1 | 1980 | 176 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1980 | 397 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 2896 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1980 | 94 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1979 | 14 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 1984 | 2085 | 0.010 |
Why?
|
| Viscosity | 1 | 1979 | 52 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1995 | 214 | 0.010 |
Why?
|
| Operating Room Technicians | 1 | 1978 | 1 | 0.010 |
Why?
|
| Analog-Digital Conversion | 1 | 1978 | 8 | 0.010 |
Why?
|
| Kaolin | 1 | 1977 | 9 | 0.010 |
Why?
|
| Sodium | 1 | 1979 | 330 | 0.010 |
Why?
|
| Blood Cell Count | 4 | 1979 | 67 | 0.010 |
Why?
|
| Punctures | 1 | 1977 | 29 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1980 | 204 | 0.010 |
Why?
|
| Equipment and Supplies | 1 | 1977 | 32 | 0.010 |
Why?
|
| Endoscopy | 1 | 1980 | 388 | 0.010 |
Why?
|
| Renal Dialysis | 2 | 1987 | 356 | 0.010 |
Why?
|
| Cattle | 2 | 1974 | 397 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 295 | 0.010 |
Why?
|
| Cysts | 1 | 1977 | 100 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1996 | 46 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1995 | 139 | 0.010 |
Why?
|
| Heparin Antagonists | 1 | 1975 | 3 | 0.010 |
Why?
|
| Prevalence | 1 | 2000 | 1393 | 0.010 |
Why?
|
| Blood Cells | 1 | 1975 | 32 | 0.010 |
Why?
|
| Illinois | 1 | 1977 | 524 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1997 | 174 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 513 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 373 | 0.010 |
Why?
|
| Esterases | 1 | 1974 | 13 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1996 | 180 | 0.010 |
Why?
|
| Silicon Dioxide | 1 | 1974 | 40 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1976 | 263 | 0.010 |
Why?
|
| Factor XIII | 1 | 1974 | 5 | 0.010 |
Why?
|
| Calcium Chloride | 1 | 1974 | 11 | 0.010 |
Why?
|
| Venoms | 1 | 1974 | 11 | 0.010 |
Why?
|
| Urea | 1 | 1974 | 54 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1974 | 40 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1975 | 238 | 0.010 |
Why?
|
| Solubility | 1 | 1974 | 187 | 0.010 |
Why?
|
| Observer Variation | 1 | 1995 | 579 | 0.010 |
Why?
|
| Heart-Lung Machine | 1 | 1973 | 5 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 890 | 0.010 |
Why?
|
| Intrinsic Factor | 1 | 1972 | 1 | 0.010 |
Why?
|
| Hemophilia B | 1 | 1972 | 5 | 0.010 |
Why?
|
| Hemophilia A | 1 | 1972 | 6 | 0.010 |
Why?
|
| Membranes, Artificial | 1 | 1973 | 39 | 0.010 |
Why?
|
| Temperature | 1 | 1974 | 442 | 0.010 |
Why?
|
| Cyclophosphamide | 2 | 1984 | 284 | 0.010 |
Why?
|
| Abortion, Septic | 1 | 1972 | 3 | 0.010 |
Why?
|
| Muscles | 1 | 1973 | 179 | 0.010 |
Why?
|
| Blood Platelet Disorders | 1 | 1972 | 13 | 0.010 |
Why?
|
| Menstruation Disturbances | 1 | 1972 | 22 | 0.010 |
Why?
|
| Ligation | 1 | 1972 | 55 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1991 | 93 | 0.010 |
Why?
|
| Fluorouracil | 2 | 1984 | 543 | 0.010 |
Why?
|
| Diagnosis, Differential | 3 | 1983 | 1570 | 0.010 |
Why?
|
| Obesity | 1 | 1978 | 1077 | 0.010 |
Why?
|
| Kinetics | 3 | 1979 | 1477 | 0.010 |
Why?
|
| Physicians | 1 | 1978 | 685 | 0.010 |
Why?
|
| Causality | 1 | 1991 | 86 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1972 | 156 | 0.000 |
Why?
|
| Necrosis | 2 | 1983 | 219 | 0.000 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1972 | 250 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1988 | 290 | 0.000 |
Why?
|
| Endopeptidases | 1 | 1988 | 114 | 0.000 |
Why?
|
| Uremia | 1 | 1987 | 14 | 0.000 |
Why?
|
| Hemoglobins | 2 | 1980 | 197 | 0.000 |
Why?
|
| Prednisolone | 1 | 1984 | 38 | 0.000 |
Why?
|
| Doxorubicin | 1 | 1984 | 285 | 0.000 |
Why?
|
| Larva | 1 | 1983 | 139 | 0.000 |
Why?
|
| Carbon Dioxide | 2 | 1973 | 201 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1973 | 489 | 0.000 |
Why?
|
| Prednisone | 1 | 1982 | 251 | 0.000 |
Why?
|
| Hyaline Membrane Disease | 1 | 1980 | 3 | 0.000 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1979 | 7 | 0.000 |
Why?
|
| Erythrocyte Count | 1 | 1978 | 21 | 0.000 |
Why?
|
| Complement System Proteins | 1 | 1978 | 87 | 0.000 |
Why?
|
| Physical Examination | 1 | 1979 | 149 | 0.000 |
Why?
|
| Synovial Cyst | 1 | 1977 | 17 | 0.000 |
Why?
|
| Mathematics | 1 | 1977 | 176 | 0.000 |
Why?
|
| Popliteal Artery | 1 | 1977 | 32 | 0.000 |
Why?
|
| Joint Diseases | 1 | 1977 | 47 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1979 | 316 | 0.000 |
Why?
|
| Elastin | 1 | 1976 | 8 | 0.000 |
Why?
|
| Dimethylpolysiloxanes | 1 | 1976 | 12 | 0.000 |
Why?
|
| Surface Properties | 1 | 1976 | 130 | 0.000 |
Why?
|
| Neutralization Tests | 1 | 1975 | 74 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1975 | 242 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1984 | 2661 | 0.000 |
Why?
|
| Oxygenators, Membrane | 1 | 1973 | 3 | 0.000 |
Why?
|
| Hyperventilation | 1 | 1973 | 12 | 0.000 |
Why?
|
| Partial Pressure | 1 | 1973 | 46 | 0.000 |
Why?
|
| Extracorporeal Circulation | 1 | 1973 | 37 | 0.000 |
Why?
|
| Blood | 1 | 1973 | 68 | 0.000 |
Why?
|
| Hypercapnia | 1 | 1973 | 50 | 0.000 |
Why?
|
| Microelectrodes | 1 | 1973 | 88 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1979 | 843 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1977 | 845 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1973 | 96 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1979 | 826 | 0.000 |
Why?
|
| Lung | 1 | 1977 | 1408 | 0.000 |
Why?
|
| Models, Biological | 1 | 1977 | 1805 | 0.000 |
Why?
|
| Heart Rate | 1 | 1973 | 534 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1973 | 528 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1976 | 2577 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1979 | 2471 | 0.000 |
Why?
|